drug_type
RELEVANT_DRUG
intervention_type
Biologic bispecific antibody (T-cell engager)
drug_description
CD19xCD3 bispecific T-cell engager that redirects T cells to lyse CD19+ B-ALL blasts.
nci_thesaurus_concept_id
C62528
nci_thesaurus_preferred_term
Blinatumomab
nci_thesaurus_definition
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.
drug_mesh_term
Blinatumomab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific T-cell engager that binds CD19 on B cells and CD3 on T cells, bringing them into proximity to activate T cells and induce perforin/granzyme-mediated lysis of CD19-positive B-ALL blasts.
drug_name
Blinatumomab
nct_id_drug_ref
NCT06387121